Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Ranibizumab is a monoclonal antibody fragment obtained from the same parental murine antibody as bevacizumab. It is an anti-angiogenic drug that has been approved for the treatment of AMD patients.
This report presents a comprehensive overview, market shares and growth opportunities of Ranibizumab market by product type, application, key companies and key regions. Biomedicine has achieved rapid growth in the global pharmaceutical market due to its high pharmacological activity, strong specificity, and good therapeutic effect. In the biopharmaceutical market, the monoclonal antibody is the most subdivided category. With the development of biotechnology, the research on monoclonal antibodies will be further deepened, and the patients' demand for monoclonal antibodies will also be further increased. Ranibizumab is mainly used for the treatment of age-related macular degeneration (AMD), a retinal disease that increases the incidence with age and causes a significant decrease in vision. Diabetic retinopathy and diabetic macular edema can also be treated with ranibizumab. Therefore, the deepening of global aging and the increasing incidence of chronic diseases such as diabetes will promote the expansion of demand for ranibizumab.
Indian pharmaceutical company Intas Pharmaceuticals has launched RAZUMAB™, a biosimilar of Lucentis® (Ranibizumab). The product is entirely manufactured in India, and the price of RAZUMAB™ is much cheaper than Lucentis®, which will allow the drug to be used in a wider patient population.
Ranibizumab market report explains the definition, types, applications, major countries, and major players of the Ranibizumab market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Novartis
Genentech
By Type:
Single-use prefilled syringe
Single-use glass vial
By End-User:
AMD
Diabetic Retinopathy (DR)
Diabetic Macular Edema (DME)
mCNV
RVO
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Ranibizumab Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Ranibizumab Outlook to 2028- Original Forecasts
-
2.2 Ranibizumab Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Ranibizumab Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Ranibizumab Market- Recent Developments
-
6.1 Ranibizumab Market News and Developments
-
6.2 Ranibizumab Market Deals Landscape
7 Ranibizumab Raw Materials and Cost Structure Analysis
-
7.1 Ranibizumab Key Raw Materials
-
7.2 Ranibizumab Price Trend of Key Raw Materials
-
7.3 Ranibizumab Key Suppliers of Raw Materials
-
7.4 Ranibizumab Market Concentration Rate of Raw Materials
-
7.5 Ranibizumab Cost Structure Analysis
-
7.5.1 Ranibizumab Raw Materials Analysis
-
7.5.2 Ranibizumab Labor Cost Analysis
-
7.5.3 Ranibizumab Manufacturing Expenses Analysis
8 Global Ranibizumab Import and Export Analysis (Top 10 Countries)
-
8.1 Global Ranibizumab Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Ranibizumab Export by Region (Top 10 Countries) (2017-2028)
9 Global Ranibizumab Market Outlook by Types and Applications to 2022
-
9.1 Global Ranibizumab Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Single-use prefilled syringe Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Single-use glass vial Consumption and Growth Rate (2017-2022)
-
9.2 Global Ranibizumab Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global AMD Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Diabetic Retinopathy (DR) Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Diabetic Macular Edema (DME) Consumption and Growth Rate (2017-2022)
-
9.2.4 Global mCNV Consumption and Growth Rate (2017-2022)
-
9.2.5 Global RVO Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Ranibizumab Market Analysis and Outlook till 2022
-
10.1 Global Ranibizumab Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Ranibizumab Consumption (2017-2022)
-
10.2.2 Canada Ranibizumab Consumption (2017-2022)
-
10.2.3 Mexico Ranibizumab Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Ranibizumab Consumption (2017-2022)
-
10.3.2 UK Ranibizumab Consumption (2017-2022)
-
10.3.3 Spain Ranibizumab Consumption (2017-2022)
-
10.3.4 Belgium Ranibizumab Consumption (2017-2022)
-
10.3.5 France Ranibizumab Consumption (2017-2022)
-
10.3.6 Italy Ranibizumab Consumption (2017-2022)
-
10.3.7 Denmark Ranibizumab Consumption (2017-2022)
-
10.3.8 Finland Ranibizumab Consumption (2017-2022)
-
10.3.9 Norway Ranibizumab Consumption (2017-2022)
-
10.3.10 Sweden Ranibizumab Consumption (2017-2022)
-
10.3.11 Poland Ranibizumab Consumption (2017-2022)
-
10.3.12 Russia Ranibizumab Consumption (2017-2022)
-
10.3.13 Turkey Ranibizumab Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Ranibizumab Consumption (2017-2022)
-
10.4.2 Japan Ranibizumab Consumption (2017-2022)
-
10.4.3 India Ranibizumab Consumption (2017-2022)
-
10.4.4 South Korea Ranibizumab Consumption (2017-2022)
-
10.4.5 Pakistan Ranibizumab Consumption (2017-2022)
-
10.4.6 Bangladesh Ranibizumab Consumption (2017-2022)
-
10.4.7 Indonesia Ranibizumab Consumption (2017-2022)
-
10.4.8 Thailand Ranibizumab Consumption (2017-2022)
-
10.4.9 Singapore Ranibizumab Consumption (2017-2022)
-
10.4.10 Malaysia Ranibizumab Consumption (2017-2022)
-
10.4.11 Philippines Ranibizumab Consumption (2017-2022)
-
10.4.12 Vietnam Ranibizumab Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Ranibizumab Consumption (2017-2022)
-
10.5.2 Colombia Ranibizumab Consumption (2017-2022)
-
10.5.3 Chile Ranibizumab Consumption (2017-2022)
-
10.5.4 Argentina Ranibizumab Consumption (2017-2022)
-
10.5.5 Venezuela Ranibizumab Consumption (2017-2022)
-
10.5.6 Peru Ranibizumab Consumption (2017-2022)
-
10.5.7 Puerto Rico Ranibizumab Consumption (2017-2022)
-
10.5.8 Ecuador Ranibizumab Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Ranibizumab Consumption (2017-2022)
-
10.6.2 Kuwait Ranibizumab Consumption (2017-2022)
-
10.6.3 Oman Ranibizumab Consumption (2017-2022)
-
10.6.4 Qatar Ranibizumab Consumption (2017-2022)
-
10.6.5 Saudi Arabia Ranibizumab Consumption (2017-2022)
-
10.6.6 United Arab Emirates Ranibizumab Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Ranibizumab Consumption (2017-2022)
-
10.7.2 South Africa Ranibizumab Consumption (2017-2022)
-
10.7.3 Egypt Ranibizumab Consumption (2017-2022)
-
10.7.4 Algeria Ranibizumab Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Ranibizumab Consumption (2017-2022)
-
10.8.2 New Zealand Ranibizumab Consumption (2017-2022)
11 Global Ranibizumab Competitive Analysis
-
11.1 Novartis
-
11.1.1 Novartis Company Details
-
11.1.2 Novartis Ranibizumab Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Novartis Ranibizumab Main Business and Markets Served
-
11.1.4 Novartis Ranibizumab Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Genentech
-
11.2.1 Genentech Company Details
-
11.2.2 Genentech Ranibizumab Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Genentech Ranibizumab Main Business and Markets Served
-
11.2.4 Genentech Ranibizumab Product Portfolio
-
11.2.5 Recent Research and Development Strategies
12 Global Ranibizumab Market Outlook by Types and Applications to 2028
-
12.1 Global Ranibizumab Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Single-use prefilled syringe Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Single-use glass vial Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Ranibizumab Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global AMD Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Diabetic Retinopathy (DR) Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Diabetic Macular Edema (DME) Consumption Forecast and Growth Rate (2022-2028)
-
12.2.4 Global mCNV Consumption Forecast and Growth Rate (2022-2028)
-
12.2.5 Global RVO Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Ranibizumab Market Analysis and Outlook to 2028
-
13.1 Global Ranibizumab Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Ranibizumab Consumption Forecast (2022-2028)
-
13.2.2 Canada Ranibizumab Consumption Forecast (2022-2028)
-
13.2.3 Mexico Ranibizumab Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Ranibizumab Consumption Forecast (2022-2028)
-
13.3.2 UK Ranibizumab Consumption Forecast (2022-2028)
-
13.3.3 Spain Ranibizumab Consumption Forecast (2022-2028)
-
13.3.4 Belgium Ranibizumab Consumption Forecast (2022-2028)
-
13.3.5 France Ranibizumab Consumption Forecast (2022-2028)
-
13.3.6 Italy Ranibizumab Consumption Forecast (2022-2028)
-
13.3.7 Denmark Ranibizumab Consumption Forecast (2022-2028)
-
13.3.8 Finland Ranibizumab Consumption Forecast (2022-2028)
-
13.3.9 Norway Ranibizumab Consumption Forecast (2022-2028)
-
13.3.10 Sweden Ranibizumab Consumption Forecast (2022-2028)
-
13.3.11 Poland Ranibizumab Consumption Forecast (2022-2028)
-
13.3.12 Russia Ranibizumab Consumption Forecast (2022-2028)
-
13.3.13 Turkey Ranibizumab Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Ranibizumab Consumption Forecast (2022-2028)
-
13.4.2 Japan Ranibizumab Consumption Forecast (2022-2028)
-
13.4.3 India Ranibizumab Consumption Forecast (2022-2028)
-
13.4.4 South Korea Ranibizumab Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Ranibizumab Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Ranibizumab Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Ranibizumab Consumption Forecast (2022-2028)
-
13.4.8 Thailand Ranibizumab Consumption Forecast (2022-2028)
-
13.4.9 Singapore Ranibizumab Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Ranibizumab Consumption Forecast (2022-2028)
-
13.4.11 Philippines Ranibizumab Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Ranibizumab Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Ranibizumab Consumption Forecast (2022-2028)
-
13.5.2 Colombia Ranibizumab Consumption Forecast (2022-2028)
-
13.5.3 Chile Ranibizumab Consumption Forecast (2022-2028)
-
13.5.4 Argentina Ranibizumab Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Ranibizumab Consumption Forecast (2022-2028)
-
13.5.6 Peru Ranibizumab Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Ranibizumab Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Ranibizumab Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Ranibizumab Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Ranibizumab Consumption Forecast (2022-2028)
-
13.6.3 Oman Ranibizumab Consumption Forecast (2022-2028)
-
13.6.4 Qatar Ranibizumab Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Ranibizumab Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Ranibizumab Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Ranibizumab Consumption Forecast (2022-2028)
-
13.7.2 South Africa Ranibizumab Consumption Forecast (2022-2028)
-
13.7.3 Egypt Ranibizumab Consumption Forecast (2022-2028)
-
13.7.4 Algeria Ranibizumab Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Ranibizumab Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Ranibizumab Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Ranibizumab
-
Figure of Ranibizumab Picture
-
Table Global Ranibizumab Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Ranibizumab Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Single-use prefilled syringe Consumption and Growth Rate (2017-2022)
-
Figure Global Single-use glass vial Consumption and Growth Rate (2017-2022)
-
Figure Global AMD Consumption and Growth Rate (2017-2022)
-
Figure Global Diabetic Retinopathy (DR) Consumption and Growth Rate (2017-2022)
-
Figure Global Diabetic Macular Edema (DME) Consumption and Growth Rate (2017-2022)
-
Figure Global mCNV Consumption and Growth Rate (2017-2022)
-
Figure Global RVO Consumption and Growth Rate (2017-2022)
-
Figure Global Ranibizumab Consumption by Country (2017-2022)
-
Table North America Ranibizumab Consumption by Country (2017-2022)
-
Figure United States Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Canada Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Mexico Ranibizumab Consumption and Growth Rate (2017-2022)
-
Table Europe Ranibizumab Consumption by Country (2017-2022)
-
Figure Germany Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure UK Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Spain Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Belgium Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure France Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Italy Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Denmark Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Finland Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Norway Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Sweden Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Poland Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Russia Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Turkey Ranibizumab Consumption and Growth Rate (2017-2022)
-
Table APAC Ranibizumab Consumption by Country (2017-2022)
-
Figure China Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Japan Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure India Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure South Korea Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Thailand Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Singapore Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Philippines Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Ranibizumab Consumption and Growth Rate (2017-2022)
-
Table South America Ranibizumab Consumption by Country (2017-2022)
-
Figure Brazil Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Colombia Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Chile Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Argentina Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Peru Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Ranibizumab Consumption and Growth Rate (2017-2022)
-
Table GCC Ranibizumab Consumption by Country (2017-2022)
-
Figure Bahrain Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Oman Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Qatar Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Ranibizumab Consumption and Growth Rate (2017-2022)
-
Table Africa Ranibizumab Consumption by Country (2017-2022)
-
Figure Nigeria Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure South Africa Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Egypt Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure Algeria Ranibizumab Consumption and Growth Rate (2017-2022)
-
Table Oceania Ranibizumab Consumption by Country (2017-2022)
-
Figure Australia Ranibizumab Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Ranibizumab Consumption and Growth Rate (2017-2022)
-
Table Novartis Company Details
-
Table Novartis Ranibizumab Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Ranibizumab Main Business and Markets Served
-
Table Novartis Ranibizumab Product Portfolio
-
Table Genentech Company Details
-
Table Genentech Ranibizumab Sales, Price, Value and Gross Profit (2017-2022)
-
Table Genentech Ranibizumab Main Business and Markets Served
-
Table Genentech Ranibizumab Product Portfolio
-
Figure Global Single-use prefilled syringe Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Single-use glass vial Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global AMD Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Diabetic Retinopathy (DR) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Diabetic Macular Edema (DME) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global mCNV Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global RVO Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Ranibizumab Consumption Forecast by Country (2022-2028)
-
Table North America Ranibizumab Consumption Forecast by Country (2022-2028)
-
Figure United States Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Ranibizumab Consumption Forecast by Country (2022-2028)
-
Figure Germany Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Ranibizumab Consumption Forecast by Country (2022-2028)
-
Figure China Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Ranibizumab Consumption Forecast by Country (2022-2028)
-
Figure Brazil Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Ranibizumab Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Ranibizumab Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Ranibizumab Consumption Forecast by Country (2022-2028)
-
Figure Australia Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Ranibizumab Consumption Forecast and Growth Rate (2022-2028)
-
